UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K/A
(Amendment No. 1)
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
December 23, 2015
IMMUNE DESIGN CORP.
(Exact name of registrant as specified in its charter)
| | | | |
| Delaware | | 001-36561 | | 26-2007174 |
(state or other jurisdiction of incorporation) | | (Commission File Number) | | (I.R.S. Employer Identification No.) |
| | |
1616 Eastlake Ave. E., Suite 310 Seattle, Washington | | 98102 |
| (Address of principal executive offices) | | (Zip Code) |
Registrant’s telephone number, including area code: (206) 682-0645
(Former name or former address, if changed since last report)
Check the appropriate box below if theForm 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant toRule 14a-12 under the Exchange Act (17 CFR240.14a-12) |
| ¨ | Pre-commencement communications pursuant toRule 14d-2(b) under the Exchange Act (17 CFR240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant toRule 13e-4(c) under the Exchange Act (17 CFR240.13e-4(c)) |
Explanatory Note
On December 30, 2015, Immune Design Corp. (the “Company”) filed a Current Report onForm 8-K (the “Original Report”) to report, among other things, that the Company entered into a second amended and restated license agreement (the “Restated Agreement”) with the Infectious Disease Research Institute. This Current Report onForm 8-K/A amends the Original Report solely to file the Restated Agreement as an exhibit hereto. The other disclosures made in the Original Report remain unchanged.
Item 9.01. Financial Statements and Exhibits.
| | |
Exhibit
Number | | Description |
| |
| 10.1† | | Second Amended and Restated License Agreement, by and between the Company and the Infectious Disease Research Institute, a Washington not-for-profit corporation, dated December 23, 2015. |
| † | Confidential portions of this exhibit have been redacted and filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request in accordance withRule 24b-2 of the Securities Exchange Act of 1934, as amended. |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | |
| IMMUNE DESIGN CORP. |
| |
| By: | | /s/ Carlos Paya, M.D., Ph.D. |
| | Carlos Paya, M.D., Ph.D. President and Chief Executive Officer |
Dated: February 16, 2016
EXHIBIT INDEX
| | |
Exhibit No. | | Description |
| |
| 10.1† | | Second Amended and Restated License Agreement, by and between the Company and the Infectious Disease Research Institute, a Washington not-for-profit corporation, dated December 23, 2015. |
| † | Confidential portions of this exhibit have been redacted and filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request in accordance withRule 24b-2 of the Securities Exchange Act of 1934, as amended. |
